We have performed univariate and multivariate analysis to determine the factors that affect the kinetics of neutrophil and platelet recovery in 546 recipients of T cell-depleted (TCD) marrow allografts. All patients received marrow depleted of mature CD3
While awaiting engraftment following a progenitor cell transplant, the patient is at high risk of infection and bleeding due to the absence or low numbers of neutrophils and platelets, respectively. Recipients of allogeneic grafts are at increased risk for infections compared to recipients of autologous grafts due to the use of potent immunosuppressive agents to prevent graft-versus-host disease (GVHD) or graft rejection. In addition to treatment with immunosuppression, many recipients of allogeneic grafts receive prophylactic anti-viral or antibiotic therapy that may further delay progenitor cell engraftment.
T cell depletion of marrow allografts by almost every method described reduces the incidence and severity of acute GVHD thus reducing the need for GVHD treatment that may delay engraftment (reviewed in Ref. 1) . The processing required for the removal of mature T cells from the marrow graft frequently results in a loss of CD34 ϩ progenitor cells compared to unmanipulated grafts. T cell depletion has been associated with a higher rate of graft failure, most likely due to loss of the allogeneic activity of T cells in the graft against residual host-derived T cells that survive the conditioning regimen. 2 The loss of CD34 ϩ progenitors due to processing may further delay the time to engraftment.
Recombinant human growth factor support following allogeneic progenitor cell transplantation has been widely used to shorten the duration of neutropenia (reviewed in Ref. 3 ). Both granulocyte colony-stimulating factor (G-CSF) and granulocyte/macrophage colony-stimulating factor (GM-CSF) have been successfully used for this purpose and have been shown to reduce the time to neutrophil recovery by 1-4 days in most reported studies. 4, 5 Platelet recovery, in contrast, may be accelerated, delayed, or unaffected depending on the study. [6] [7] [8] [9] The source of progenitor cells, marrow vs peripheral blood, also affects engraftment kinetics with PBPCs clearly showing a faster recovery of both neutrophils and platelets. 5 Similar results are found for autologous transplants including the variable reported effects of growth factor use on platelet recovery. [10] [11] [12] [13] In the autologous setting increasing the dose of CD34 ϩ progenitors in the PBPC graft to a threshold level of 2 ϫ 10 6 /kg for neutrophils and 5 ϫ 10 6 /kg for platelets maximizes the rate of engraftment. 14, 15 Here, the correlation of cell dose with engraftment kinetics appears to be even more pronounced when considering the CD34 ϩ CD38 Ϫ subset. 16 There are fewer studies that analyze the effects of growth factor use, CD34 ϩ dose or other patient or donor characteristics on engraftment kinetics in recipients of T celldepleted (TCD) marrow grafts. However, it would appear that neutrophil engraftment is accelerated with growth factor treatment in this setting as well. 17, 18 In this report, we retrospectively analyzed data from 546 recipients of a TCD allograft for patient, donor, and graft factors that may affect engraftment kinetics. We specifically focused on factors known at the time of transplant that might be used to predict the time of engraftment. Factors identified from univariate analysis were used to construct multivariate statistical models to identify the variables that independently affected neutrophil and platelet recovery in this heterogeneous patient group.
Patients and methods

Patients
Between January 1990 and December 1999 a total of 546 patients received a primary transplant of TCD marrow at the Medical College of Wisconsin. Of these, 31 patients failed to achieve engraftment to an ANC of 0.5 ϫ 10 9 /l either due to primary graft failure (n = 17), or early death due to conditioning toxicity or infection (n = 14). Seven additional patients who died before receiving their progenitor cell graft were not included in the analysis. All patients received marrow that was TCD by complement-mediated lysis using either T 10 B 9 Ϫ1A3 (n = 462) (prepared locally as ascites or as purified antibody for all cases performed after January 1996) or Muromonab-Orthoclone OKT3 (n = 53) (Ortho Biotech, Raritan, NJ, USA) monoclonal antibody to remove CD3 ϩ T lymphocytes. The log depletion of clonable T cells using T 10 B 9 -1A3 was 1.94 Ϯ 0.46 and with Muromonab-Orthoclone OKT3 it was 1.67 Ϯ 0.44.
Patients received a standard conditioning regimen consisting of intravenous cytarabine (3 g/m 2 every 12 h for six doses days Ϫ7 -to Ϫ4), cyclophosphamide (45 mg/kg given 6 h after the second and fourth doses of cytarabine, methylprednisolone (1 g/m 2 every 12 h on days Ϫ2, Ϫ1) (total two doses), and 14 Gy total body irradiation. 19 At the discretion of the attending physician, the cytarabine dose was reduced 25-50% for those patients over the age of 40 years (n = 76). Patients with aplastic anemia were treated in an identical fashion with the exception that 16 of the 36 patients were given anti-thymocyte globulin (ATG) at a dose of 15 mg/kg/day from days 4 to 10 (total seven doses) as a result of a protocol modification made in August 1994 to promote engraftment. 20 All patients received GVHD chemoprophylaxis consisting of cyclosporine administered as an intravenous infusion beginning day Ϫ1 at 3 mg/kg per day and eventually changed to a corresponding oral dose when tolerated. Recipients of allografts from a haplotype identical donor (n = 56) received ATG at a dose of 15 mg/kg/day from days 4 to 10 post transplant and methylprednisolone in two daily doses of 1 mg/kg/day on days ϩ2 to ϩ17, one dose on day ϩ18 and then tapered to day ϩ35. An additional six recipients of unrelated marrow received an identical course of ATG due to T cell depletion that was less than 1.0 log by flow cytometry analysis. Patient donor, and graft characteristics that were considered in the analysis are listed in Table 1 . 
Factors assessed
Outcomes: Neutrophil engraftment was defined as the first of 3 consecutive days with a sustained neutrophil count of 0.5 ϫ 10 9 /l. Platelet engraftment was the first of three consecutive platelet counts unsupported by transfusion of 20 ϫ 10 9 /l.
Variables:
The variables that were assessed in this analysis are included in Table 1 . Patients were stratified based on the use and type of growth factor used post transplant to facilitate engraftment. Only patients starting a growth factor(s) within 7 days post transplant were included in the growth factor group. G-CSF was administered at 5 g/kg/s.c./day or rounded to the nearest vial size (usually 480 g) starting either on day 0 (n = 33), day ϩ1 (n = 44) or between days ϩ2 and ϩ7 (n = 25). GM-CSF was administered at 250-500 g/m 2 /s.c./day starting at either day 0 (n = 49), day ϩ1 (n = 29) or between days ϩ2 and ϩ7 (n = 7). A subset of 55 patients started both G-CSF and GM-CSF during week 1 post BMT as part of a clinical protocol. Most (n = 38) of these patients received growth factors beginning on day 0 and approximately 1/2 of the patients received G-CSF 2 days prior to starting GM-CSF. When used, growth factors were administered until sustained neutrophil engraftment was Ն1.0 ϫ 10 9 /l. Three hundred and four patients did not receive growth factor during the first week post transplant. The decision to use growth factors for a given patient group and the growth factor used was a function of the BMT program policy in place at the time of transplant.
Anti-thymocyte globulin (ATG) use was considered only if started during the first week post transplant, with most patients started on day ϩ4 and continued for either 7 or 14 days.
HLA matching was performed based on HLA-A, HLA-B (class I), and HLA-DRB1, HLA-DQB (class II). All patients were typed for class II at the DNA level either using oligonucleotide typing 21 or DNA sequencing. 22 All patients were typed for class I by serology and a subset of donor/recipient pairs were typed retrospectively (n = 130) by class I DNA sequencing and/or one-dimensional isoelectric focusing 23 or prospectively (n = 50) by DNA sequencing. Antigen match was assigned based on the highest level of typing performed.
The CD34 ϩ cell content of the graft was known for a subset of 249 donor/recipient pairs transplanted since October 1994. CD34 ϩ cells were measured in the TCD marrow by flow cytometry using the ISHAGE gating method and was analyzed as CD34 ϩ cells/kg infused with the marrow graft. 24, 25 T cell content was measured by a sensitive limiting dilution assay for total clonable T cells and was analyzed as T cells/kg infused with the marrow graft. 26 
Statistical analysis
Associations between patient, donor or graft factors that might affect the kinetics of neutrophil or platelet engraftment were evaluated in a univariate analysis by determining the probability of engraftment at each of 2 tarBone Marrow Transplantation get days for neutrophils (day 14 and day 21) and platelets (day 25 and day 35). For each target day the engraftment probability Ϯ s.e.m. were estimated for each level of a possible prognostic factor using the Kaplan-Meier estimator. A test of the hypothesis of equality in engraftment probabilities was constructed using the assumed large sample normality of the estimates by standard methods. In this and in the subsequent multivariate analysis patients who did not reach a given endpoint were censored at the time of death, second BMT or last assessment. The variables that were considered included those listed in Table 1 . Patient age, donor age and T cell dose were stratified based on the median of the group. Patient diagnosis at BMT, gender differences between donor and recipient, HLA matching based on the relationship of the donor and the number of antigens mismatched, CMV status of patient and donor, CD34 ϩ cell dose, and growth factor type were each stratified into three or more groups as indicated in Table 2 . ATG was stratified as used (if given during the first week post transplant) or not used. Patients who were dose reduced during conditioning (n = 76) were compared to those who did not receive dose reduction. Missing data for CD34 ϩ cell dose and for T cell dose were coded as an 'unknown' strata for the analysis. The results obtained have a larger confidence interval than would have been seen had all data been available.
Multivariate analysis of factors affecting engraftment was performed using the Cox proportional hazards regression model considering the factors identified in the univariate analysis. In this model the relative risk of a variable is ratio of the engraftment rates of patients that are identical except for the variable under study. A relative risk of 2, for example, indicates that the subject with the factor engrafts at a rate twice that of a subject without the factor in the baseline group. The Cox model assumes that the ratio of these hazard rates is constant over time so that the relative risk is constant over time. The assumption of proportional hazards was tested by using a time-dependent covariate. Age was assessed as a continuous variable for both patient and donor as well as for the interaction between patient and donor age with the relative risk expressed per year of increasing age. Diagnosis at transplant was further stratified based on risk, with standard risk defined as disease in first or second complete remission (CR) or CML in chronic phase, and high risk as patients in CR3, CML in accelerated or blast phase, or with active or refractory disease.
Results
Univariate analysis
The engraftment probabilities at each of the two neutrophil and platelet assessment days and the significance of the differences between the strata are summarized in Table 2 . Patient age, but not donor age (not shown) was associated with a difference in engraftment kinetics. Younger patients (18 years or younger) were less likely to achieve neutrophil engraftment by either day 14 (P = 0.0004) or day 21 (P = 0.0008) than patients older than 18 years but were more likely to achieve platelet engraftment early (by day 25, P = 0.0003) than older patients. The median day of neutrophil engraftment was 17 for younger patients vs 15 for those over 18 years. Median platelet engraftment was on day 27 and day 31 for younger and older patients, respectively. Conditioning dose reduction in a subset of the patients over 40 years (n = 76) was not associated with either neutrophil or platelet engraftment (data not shown).
Gender differences between patient and donor appeared to affect the probability of engraftment at the earlier time periods for both neutrophils (P = 0.0022) and platelets (P = 0.0022). The lowest probabilities for neutrophil engraftment by day 14 and platelet engraftment by day 25 were seen for female recipients of male donor grafts, although a significant difference was not seen at the later engraftment assessment period.
Engraftment kinetics also differed based on primary disease type, with patients transplanted for acute leukemia or aplastic anemia having a lower probability for early (P = 0.0003) and later (P = 0.0009) neutrophil engraftment.
Significant differences were not seen in any disease strata for early platelet engraftment, although patients with aplastic anemia trended towards a lower probability of later platelet engraftment.
Significant differences in engraftment probabilities based on HLA disparity and donor source were seen only for day 35 platelet engraftment (P Ͻ 0.0001). Here, related and nonrelated recipients of grafts with two or more disparities were less likely to engraft by day 35, while recipients of matched sibling grafts were most likely to engraft by this day.
CMV serostatus had borderline effects on engraftment kinetics (P = 0.0484). Seropositive recipients of seropositive donor grafts had a somewhat higher probability of early neutrophil engraftment and a lower probability of early platelet engraftment than seronegative recipients of seronegative donor grafts.
ATG appeared to have a highly significant effect on both neutrophil and platelet engraftment (P = Ͻ0.0003 for all measurements). ATG use was associated with a higher probability of neutrophil engraftment, and conversely a lower probability of platelet engraftment on each of the assessment days. Patients receiving ATG engrafted neutrophils at a median of day 14 vs day 17 without ATG, and had a median platelet engraftment time of day 43 with ATG compared to day 28 without ATG.
Growth factor use was a particularly strong predictor of engraftment kinetics (any vs none) as shown in Figure 1 . The growth factor effect differed based on the specific growth factor or growth factor combination that was used during the first week post transplant, Figure 2 and Table 2 . Patients who did not receive growth factor were the least likely to achieve early or later neutrophil engraftment but were more likely to achieve platelet engraftment at both assessment times than any of the other strata. The strongest growth factor effects were seen in recipients of G-CSF who were most likely to engraft neutrophils and least likely to engraft platelets compared to the other strata. The engraftment kinetics of patients receiving both G-CSF and GM-CSF were most similar to patients receiving G-CSF alone as shown in Figure 2 .
A T cell dose above the median was associated with an increased probability of neutrophil engraftment by day 21 (P = 0.0356), but had no significant effect on platelet engraftment. Conversely, CD34
ϩ cell dose did not significantly affect the rate of neutrophil engraftment, but did sig- /kg dose. Platelet engraftment was especially rapid for patients receiving more than 5 ϫ 10 6 CD34 ϩ cells/kg (median day 23) as shown in Figure 3 .
Multivariate analysis
Our patients were composed of a heterogenous group in which the variables shown to have a significant effect on engraftment kinetics in the univariate analysis were not randomly distributed (data not shown). In order to determine which variables were acting independently the models for the multivariate analysis were constructed using the significant variables identified in the univariate analysis. Stratification was similar to the univariate analysis except that patient and donor age were considered as linear terms and further stratification of disease groups by risk was included. Independent factors associated with a more rapid neutrophil engraftment included the dose of CD34 ϩ cells, and growth factor administration. Platelet engraftment was affected by both of these variables as well as by diagnosis and HLA mismatch. The results of this analysis, expressed Effect of growth factor type on engraftment kinetics. The data are stratified by growth factor type and are shown as the probability of engraftment over time to neutrophils of 0.5 ϫ 10 9 /1 (a) or platelets to 20 ϫ 10 9 /1 (b). Patients were censored at death, at the time of second transplant or immunotherapy procedure or at the time of last assessment. The probability of neutrophil engraftment on day 14 and day 21 based on growth factor type was significantly different (P Ͻ 0.0001) for both assessment times as was the probability of platelet engraftment on day 25 and day 35 (both P Ͻ 0.0001). as the relative risk (RR) compared to the baseline strata are shown in Table 3 .
Growth factor use had a highly significant effect on both neutrophil and platelet engraftment. Growth factor combinations including G-CSF showed nonproportional hazards for both neutrophil and platelet engraftment. A timedependent covariate was used to fit the models for different constant relative risks in different time periods. For neutrophil engraftment, recipients of G-CSF alone were 9.5 times more likely to have reached 0.5 ϫ 10 9 /l by day 12 compared to patients not receiving growth factor and were 2.1 times more likely to reach 0.5 ϫ 10 9 /l on any day after day 12. The effect of GM-CSF alone on neutrophil engraftment was constant over the entire engraftment period, and was less than G-CSF (RR = 1.8) . The combination of G-CSF ϩ GM-CSF also showed a nonproportionate effect that was greater early after transplant (3.0 relative risk within the first 18 days). Combination growth factor use was not better than G-CSF alone in speeding neutrophil recovery.
As seen in the univariate analysis, growth factor use delayed platelet engraftment, with the longest delays involving use of G-CSF. The likelihood that platelet engraftment would be delayed was greatest for patients who engrafted to 20 ϫ 10 9 /l by day 25 (RR = 0.4, P = 0.0004) for the group receiving only G-CSF, and was most pronounced for patients engrafting by day 35 for the combination of G-CSF and GM-CSF (RR = 0.5, P = 0.007). The delay in platelet engraftment caused by GM-CSF used alone was not significant in the multivariate analysis as shown in Table 3 . Likewise, the effects of CD34 ϩ cell dose remained highly significant as a predictor of platelet engraftment, and became significant at the highest dose level, 5 ϫ 10 6 CD34 ϩ cells/kg (RR = 1.7, P = 0.0154), for more rapid neutrophil engraftment when adjusting for other variables.
There were no significant effects of disease on neutrophil engraftment, although lymphoma was associated with somewhat faster neutrophil recovery (RR = 1.4, P = 0.09) compared to the acute leukemia baseline. Chronic leukemia predicted a significantly faster platelet engraftment (RR = 1.5, P = 0.005) while patients with aplastic anemia had delayed platelet engraftment (RR = 0.6, P = 0.015) relative to the baseline stratum. Further stratification of disease by risk did not result in significant association with neutrophil or platelet engraftment.
Both patient age and donor age were considered as linear terms. There was no effect on engraftment kinetics due to donor age. However, for each year increase in patient age, the risk of platelet engraftment decreased with a relative risk of 0.98 compared to 1 year younger (P = 0.011). The effects of patient age were the same for all donor ages as shown by an insignificant age interaction term. Neither donor nor patient age significantly affected neutrophil engraftment.
Platelet engraftment was most significantly delayed in patients who received a graft from a donor who was у2 HLA allele mismatched, whether related or nonrelated (P Ͻ 0.0001). Grafts from matched or 1 antigen mismatched nonrelated donors were also associated with a lower relative risk of platelet engraftment as shown in Table 3 . The effects of HLA matching on neutrophil engraftment were not significant.
The effect of ATG in enhancing granulocyte engraftment and delaying platelet engraftment was not seen in the multivariate analysis. Neither were there significant independent effects of T cell dose, CMV status or gender when other variables were considered.
Discussion
It was clear from the multivariate results that some patient and donor variables that are not easily controlled are important factors affecting engraftment kinetics. For example, the primary disease for which the patient was transplanted was an independent variable affecting the rate of both neutrophil and platelet engraftment, although in different ways. A pretransplant diagnosis of acute leukemia was associated with a slower rate of platelet engraftment as compared to chronic leukemia. This may possibly be due to damage caused to the marrow microenvironment by pretreatment with one or more cycles of intensive chemotherapy to induce remission before transplant, given that the marrow stroma remains of host origin following transplantation. 27 Patients transplanted for aplastic anemia recovered platelets even more slowly than those with acute leukemia (RR = 0.58). Here, a delay in engraftment may be due to preimmunization by minor histocompatibility antigens as a result of blood transfusions needed to support the patient prior to transplantation. 28, 29 Likewise, patient age was a significant predictor for more rapid platelet engraftment but was not significant in the multivariate analysis for neutrophil engraftment. In contrast, neither
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Where possible at our center, donor/recipient pairs are selected to be HLA compatible since HLA disparity is associated with higher rates of immune-mediated graft rejection and acute GVHD. 2 However, HLA disparity has not previously been reported to be associated with a delay in engraftment kinetics. Our study included a patient group with more complete HLA information than most reported studies due to the high resolution typing for HLA class II for all patients and extended HLA class I typing for 180 of the 398 pairs that were not HLA-identical siblings. In part because of this extended typing two or more disparities were identified in 41 unnrelated and 83 related donor transplants in this study. Using this information we found that two or more disparate HLA alleles for both related and unrelated donor transplants were highly significant (P Ͻ 0.0001) predictors for slower platelet recovery. However, even single disparities were associated with a lower relative risk of platelet engraftment compared to HLAidentical sibling transplants (Table 3) . HLA disparity had no significant effect on neutrophil engraftment. Platelet engraftment may be particularly sensitive to residual host immune reactivity to the engrafting donor progenitors. There was probably more acute GVHD in the two highly mismatched groups. Acute GVHD has been associated with shortened platelet survival and delayed platelet recovery. 30 Of most interest are factors affecting engraftment that potentially can be controlled by the clinician. The factor most easily controlled is the use and type of myeloid growth factor post transplant. Both G-CSF and GM-CSF have been widely used to speed neutrophil recovery after chemotherapy or progenitor cell transplantation. Conventionally, growth factors have been administered starting on the day of transplant. However, several trials have shown that neutrophil engraftment is the same when growth factors are started 1 day or up to 7 days post autologous 31 or allogeneic transplantation. 32, [33] [34] [35] Therefore, for the purpose of our analysis, we included a patient in a growth factor group if the growth factor was started within the first week post transplant. Consistent with other studies of allogeneic BMT, we found a significant enhancing effect of growth factor on neutrophil recovery compared to patients who did not receive growth factor. 6, 8, 9, 17, [35] [36] [37] [38] [39] [40] The mean recovery to an ANC of 0.5 ϫ 10 9 /l was 14 days for patients receiving growth factor vs 18 days for those not receiving any growth factor. However, the faster neutrophil recovery was associated with a 7 day slower median recovery of platelets, thus offsetting some of the benefit achieved. When growth factor type was considered, both G-CSF and GM-CSF resulted in faster neutrophil recovery, with G-CSF showing a stronger neutrophil effect than GM-CSF. However, the inhibiting effect on platelet engraftment was significant only for G-CSF. The combination of G-CSF ϩ GM-CSF was comparable to G-CSF alone and did not further speed neutrophil or delay platelet engraftment compared to G-CSF alone. Thus, the combined use of G-CSF with GM-CSF appears to offer no advantage, a finding also reported in autologous PBSC transplants 41 and in recipients of unmanipulated allogeneic bone marrow. 42, 43 A differential effect of G-CSF on neutrophil vs platelet recovery has also been reported in autologous PBSC grafts. 5, [13] [14] [15] However, no clear delaying effect of G-CSF on platelet engraftment has been described in the setting of allogeneic transplantation, although in many of the published studies platelet recovery was not assessed. 4, 36, 39 Significant reductions in platelet counts have been reported in neonates and children treated with G-CSF. GM-CSF treatment of children, in contrast, seems to cause an elevation in platelet counts (reviewed in Ref. 44 ). Similar to our findings, G-CSF was shown to have a more pronounced effect in enhancing neutrophil engraftment than GM-CSF when directly compared in the autologous setting. 45 These differential effects on hematopoiesis are probably due to the biological differences between G-CSF and GM-CSF. In particular, G-CSF has been shown to be the primary physiological regulator of neutrophil production, maturation and activation. 46 Indeed, receptors for G-CSF appear to be limited to the CD34 subset committed to myeloid differentiation. 47 This indicates that the ability of G-CSF to mobilize multipotent progenitors may be indirect, perhaps through the action of other cytokines induced by exposure to G-CSF. 48 GM-CSF and G-CSF possess similar physiological features. However, GM-CSF differs by acting at an earlier stage of hematopoiesis and has effects on the proliferation and differentiation of multilineage hematopoietic progenitors, including megakaryocytes. 8, 49 Thus, G-CSF may be more selective in directing the differentiation of progenitors towards the myeloid lineage, whereas GM-CSF can promote both myeloid and megakaryocyte differentiation.
Another independent variable affecting engraftment kinetics found in our study was the dose of CD34 ϩ cells administered. Prior to the development of multi-parameter flow cytometry techniques for CD34 ϩ cell detection it was difficult to obtain an accurate measure of CD34 ϩ cell content. This was especially true in bone marrow components due to the inherently higher background autofluorescence of immature progenitor cells. Most of the published data regarding the effect of CD34 ϩ cell dose are from the analysis of mobilized autologous peripheral blood, and in this setting CD34 ϩ cell content was shown to correlate with the speed of both neutrophil and platelet engraftment. 50 A threshold CD34 ϩ cell dose has been reported for recipients of autologous PBSC beyond which the rate of platelet (or neutrophil) engraftment does not improve. This dose has been shown to be greater for platelets, generally 5 ϫ 10 6 /kg vs a threshold dose of 2 ϫ 10 6 /kg for neutrophils. 14, 50, 51 It may be that platelet engraftment appeared to be enhanced or unaffected in studies where the CD34 ϩ cell dose was at or near the threshold limit such that the delaying effect of G-CSF was obscured. In both univariate and multivariate analysis, we observed a more rapid rate of engraftment when у2 ϫ 10 6 CD34 ϩ cells/kg were infused. This effect was seen regardless of the growth factor or growth factor combination used during the early engraftment period. Because of the heterogeneous nature of our patient group, it is difficult to set threshold limits for CD34 ϩ cell dose. However, it did appear that doses below 2 ϫ 10 6 CD34 ϩ cells/kg resulted in a significant delay in neutrophil and platelet engraftment while doses above 5 ϫ 10 6 CD34 ϩ cells/kg were associated with particularly rapid platelet engraftment as shown in Figure 3 . Unfortunately, unlike PBPC allografts or autografts, the CD34 ϩ cell content of a marrow allograft is less easy to control due to the limitations of the volume of marrow that may be obtained without risk to the donor. This is especially true for grafts that are to be depleted of T cells, since there may be substantial loss of CD34 ϩ cells due to the processing required. At our own center, we recover from 30 to 50% of the starting CD34 ϩ cells after T cell depletion. Based on the average nucleated cell counts and percentage of CD34 ϩ cells in marrow it is difficult to achieve CD34 ϩ cell infusion doses over 5 ϫ 10 6 /kg for adult recipients of TCD marrow. A better understanding of the variables that independently affect the kinetics of engraftment following allogeneic BMT is needed. Such knowledge may allow the clinician to make choices before and/or after the transplant that might serve to accelerate the rate of engraftment. This information may also be used to better educate the patient regarding their risks in undergoing transplant. A shorter period of neutropenia has been shown to translate to fewer infections with a possible beneficial effect on the morbidity of progenitor cell transplantation. The best way to achieve this goal would be to maximize CD34 ϩ cell dose, avoid the use of methotrexate, and use a myeloid growth factor starting within the first week post transplant. Published data would suggest that there is no or only modest cost savings when myeloid growth factors are used post allogeneic progenitor cell transplant 18 although this may improve if growth factor can be routinely started on day 7 post transplant with the same benefit. Of more concern is the delay in platelet engraftment associated with the use of G-CSF, particularly if the optimal CD34 ϩ cell dose cannot be achieved to overcome this effect. The benefits from the shorter period of neutropenia achieved with growth factor use have to be weighed against the negative aspects of growth factor use in allogeneic recipients of TCD bone marrow.
